Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.

MLA

Moccia, Alden A., et al. “Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is an Effective and Well-Tolerated Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma.” Leukemia & Lymphoma, vol. 58, no. 2, Feb. 2017, pp. 324–32. EBSCOhost, https://doi.org/10.1080/10428194.2016.1193852.

APA

Moccia, A. A., Hitz, F., Hoskins, P., Klasa, R., Power, M. M., Savage, K. J., Shenkier, T., Shepherd, J. D., Slack, G. W., Song, K. W., Gascoyne, R. D., Connors, J. M., & Sehn, L. H. (2017). Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & Lymphoma, 58(2), 324–332. https://doi.org/10.1080/10428194.2016.1193852

Chicago

Moccia, Alden A., Felicitas Hitz, Paul Hoskins, Richard Klasa, Maryse M. Power, Kerry J. Savage, Tamara Shenkier, et al. 2017. “Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is an Effective and Well-Tolerated Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma.” Leukemia & Lymphoma 58 (2): 324–32. doi:10.1080/10428194.2016.1193852.